Agenus (AGEN) AI Stock Analysis

• Market Cap: $128.86M
• Dividend Yield: N/A
• Average Volume (3M): 1.31M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.07
• Revenue Growth: -38.34%
• EPS Growth: 31.19%
• Country: US
• Employees: 316
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -1.03
• Shares Outstanding: 27,416,850
• 10 Day Avg. Volume: 2,416,471
• 30 Day Avg. Volume: 1,309,967
• PEG Ratio: -0.02
• Price to Book (P/B): -11.03
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.96
• Enterprise Value/Market Cap: 4.47
• Enterprise Value/Revenue: 1.10
• Enterprise Value/Gross Profit: 23.82
• Enterprise Value/Ebitda: -1.62
• 1Y Price Target: $13.00
• Price Target Upside: 176.60% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 52 Neutral
• Price Target: $5.00 ▲(6.38%Upside)

Agenus shows strong technical momentum and strategic partnerships that may bolster future growth. However, significant financial challenges, including persistent losses and cash flow issues, pose substantial risks. The stock's valuation remains unattractive, further tempering optimism.

Positive Factors

Capital Infusion

The partnership agreement with Zydus Lifesciences provides a significant cash infusion for Agenus, relieving near-term capital constraints.

Regulatory Progress

Agenus plans to re-engage with the FDA on potential pathway for approval of bot/bal in metastatic microsatellite stable colorectal cancer, aiming for a quicker path to market.

Strategic Collaboration

The strategic collaboration with Zydus is valued at up to $141M and aims to accelerate the clinical development of botensilimab and balstilimab while securing scaled manufacturing.

Negative Factors

Analyst Sentiment

Analyst remains Neutral until updates are provided on path to market and a better sense of if the FDA's advice has changed since last year.

Regulatory Challenges

At last year’s meeting, the FDA recommended against accelerated approval filing and requested additional data to show that BOT/BAL could lead to a survival benefit.

Uncertainty in Development Strategy

Agenus has not yet provided a strategy forward in neoadjuvant solid tumor development beyond ongoing ISTs, indicating a lack of clear future direction.

Agenus Business Overview & Revenue Model

Company Description

Agenus Inc. (AGEN) is a biotechnology company focused on the discovery and development of therapies that harness the body's immune system to combat cancer. The company operates in the healthcare sector, specifically in immuno-oncology, and offers a range of therapeutic antibodies, vaccines, and adjuvants designed to enhance immune response against tumors. Agenus is committed to developing innovative treatments that address unmet medical needs in oncology.

How the Company Makes Money

Agenus makes money primarily through the development and commercialization of its immuno-oncology products. The company's revenue streams include collaboration agreements, licensing deals, and milestone payments from partnerships with other pharmaceutical and biotechnology companies. Agenus often enters into strategic alliances to co-develop and commercialize its products, receiving upfront payments and potential royalties on sales. Additionally, the company may earn revenue from the sale of proprietary adjuvants and other immune-modulatory agents. These partnerships and licensing agreements are significant contributors to Agenus' earnings, as they provide both immediate financial support and long-term revenue potential from successful product commercialization.

Agenus Financial Statement Overview

Summary

Agenus faces significant financial challenges with declining revenues, persistent losses, and a strained balance sheet. The company's cash flow issues further compound its financial instability, posing substantial risks for future operations. Improvements in revenue generation, cost management, and balance sheet restructuring are needed to enhance financial health.

Income Statement

Agenus shows significant revenue fluctuations with recent revenue decline in TTM, highlighting volatility. Gross profit margins have been negative in recent years, indicating high cost of goods sold. The net profit margin is negative, showing a lack of profitability. EBIT and EBITDA margins are also negative, reflecting operational challenges.

Balance Sheet

The company's balance sheet shows negative stockholders' equity, indicating financial distress. The debt-to-equity ratio is not meaningful due to negative equity, but the high level of liabilities suggests significant leverage. The equity ratio is negative, indicating more liabilities than assets, which poses solvency risks.

Cash Flow

Agenus continues to experience negative operating and free cash flows, signaling cash burn. The free cash flow growth rate is negative, reflecting ongoing cash challenges. Operating cash flow to net income ratio suggests inefficient cash generation relative to net losses.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
99.52M	103.46M	156.31M	98.02M	295.67M	88.17M
	Gross Profit
24.18M	-52.55M	-81.37M	-99.23M	113.59M	-56.80M
	EBIT
-100.90M	-120.47M	-159.55M	-179.43M	42.28M	-117.23M
	EBITDA
-84.00M	-101.30M	-145.92M	-161.85M	44.02M	-114.63M
	Net Income Common Stockholders
-190.65M	-227.21M	-245.76M	-271.51M	-94.70M	-240.13M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
18.49M	40.44M	76.11M	193.36M	306.92M	99.87M
	Total Assets
200.20M	226.27M	313.91M	413.56M	465.96M	214.51M
	Total Debt
53.98M	94.87M	88.47M	78.43M	58.29M	55.73M
	Net Debt
35.49M	54.43M	12.36M	-100.25M	-233.64M	-44.14M
	Total Liabilities
262.29M	532.70M	462.30M	468.46M	418.05M	426.01M
	Stockholders Equity
-62.09M	-326.38M	-160.33M	-61.28M	34.44M	-203.67M
Cash Flow		Free Cash Flow
-145.78M	-158.89M	-234.16M	-228.44M	-23.67M	-142.56M
	Operating Cash Flow
-145.74M	-158.31M	-224.20M	-175.37M	10.14M	-139.10M
	Investing Cash Flow
-145.00K	27.00K	3.40M	-33.61M	-43.15M	-4.44M
	Financing Cash Flow
111.60M	122.84M	119.87M	95.83M	225.26M	183.85M

Agenus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGEN, the sentiment is Positive. The current price of 4.7 is above the 20-day moving average (MA) of 4.35, above the 50-day MA of 3.27, and above the 200-day MA of 3.53, indicating a bullish trend. The MACD of 0.56 indicates Positive momentum. The RSI at 56.12 is Neutral, neither overbought nor oversold. The STOCH value of 45.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AGEN.

Agenus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
FBIO	53 Neutral	$54.70M	―	-181.84%	―	-32.11%	88.12%
AGEN	52 Neutral	$128.86M	―	260.68%	―	-38.34%	31.19%
CYCC	38 Underperform	$9.18M	―	-1949.77%	―	-89.76%	80.28%
OTLK	38 Underperform	$77.99M	―	<0.01%	―	―	-29.01%
QNCX	31 Underperform	$65.02M	―	-130.90%	―	―	-55.81%

Agenus Corporate Events

Agenus Announces Strategic Collaboration with Zydus

On June 3, 2025, Agenus Inc. announced a strategic collaboration with Zydus Lifesciences Ltd. involving the sale of its manufacturing operations to Zydus for up to $125 million. This agreement includes an upfront payment of $75 million and contingent payments of up to $50 million, alongside a $16 million equity investment by Zydus in Agenus. The collaboration aims to accelerate the development and commercialization of Agenus’ cancer immunotherapy drugs, botensilimab and balstilimab (BOT/BAL), by leveraging Zydus’ manufacturing capabilities and market presence in India and Sri Lanka. This partnership is expected to enhance Agenus’ operational capacity and market reach, while also establishing Zydus’ BioCDMO business in the U.S.

The most recent analyst rating on (AGEN) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Agenus stock, see the AGEN Stock Forecast page.